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Abstract
Background: Caused by intracellular Gram-negative bacteria Brucella spp., brucellosis
is the most common bacterial zoonotic disease. Extensive studies in brucellosis have
yielded a large number of publications and data covering various topics ranging
from basic Brucella genetic study to vaccine clinical trials. To support data
interoperability and reasoning, a community-based brucellosis-specific biomedical
ontology is needed.
Results: The Brucellosis Ontology (IDOBRU: http://sourceforge.net/projects/idobru), a
biomedical ontology in the brucellosis domain, is an extension ontology of the core
Infectious Disease Ontology (IDO-core) and follows OBO Foundry principles. Currently
IDOBRU contains 1503 ontology terms, which includes 739 Brucella-specific terms, 414
IDO-core terms, and 350 terms imported from 10 existing ontologies. IDOBRU has
been used to model different aspects of brucellosis, including host infection, zoonotic
disease transmission, symptoms, virulence factors and pathogenesis, diagnosis,
intentional release, vaccine prevention, and treatment. Case studies are typically used
in our IDOBRU modeling. For example, diurnal temperature variation in Brucella
patients, a Brucella-specific PCR method, and a WHO-recommended brucellosis
treatment were selected as use cases to model brucellosis symptom, diagnosis, and
treatment, respectively. Developed using OWL, IDOBRU supports OWL-based
ontological reasoning. For example, by performing a Description Logic (DL) query in
the OWL editor Protégé 4 or a SPARQL query in an IDOBRU SPARQL server, a check of
Brucella virulence factors showed that eight of them are known protective antigens
based on the biological knowledge captured within the ontology.
Conclusions: IDOBRU is the first reported bacterial infectious disease ontology
developed to represent different disease aspects in a formal logical format. It serves
as a brucellosis knowledgebase and supports brucellosis data integration and
automated reasoning.
Background
Brucellosis is a zoonotic infectious disease caused by intracellular Gram-negative
bacteria Brucella spp. Since its initial isolation from tissue of a deceased patient by
Dr. David Bruce in 1887 [1], Brucella has been found in many animals, including
cattle, pigs, goat, sheep, dogs, fish and so on. Human brucellosis remains the most
common zoonotic disease worldwide, with more than 500, 000 new cases reported
annually [2]. The variety of its clinical manifestations makes diagnosis and treatment
difficult. Currently there is no available human brucellosis vaccine. As a select agent
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Brucella can also be used for bioterrorism [3].
Many online resources for Brucella information are available. For example, Brucella
Bioinformatics Portal (BBP) is a web portal that allows users to search and analyze
individual Brucella genes and link to more than 20 existing databases and analysis pro-
grams [4]. PATRIC Pathosystems resource supports browsing, visualization, and
detailed analyses of Brucella genomes [5]. VIOLIN vaccine database and analysis sys-
tem stores information of licensed Brucella vaccines and vaccine candidates [6]. The
Brucella data collected in these resources has been widely used for various purposes by
researchers around the world. However, the following bottlenecks prevent advanced
data exchange and integration among these online resources: (1) frequent use of differ-
ent terminologies for the same concepts, (2) a lack of logical and machine-readable
relations among different terms, and (3) a lack of machine-readable and community-
s u p p o r t e dd a t ae x c h a n g ef o r m a t( e.g., the OWL format) for representation of the
Brucella data. These obstacles prevent computer-assisted automated reasoning.
Biomedical ontologies are sets of hierarchical terms and relations that represent entities
in the biomedical science and show how these entities relate to each other. To support
automated reasoning, ontological terms are often expressed in formal logic, together with
documentation and definitions [7-9]. Biomedical ontologies play important roles in areas
such as knowledge management (including data indexing and information retrieval); data
integration, exchange and semantic interoperability; and decision support and reasoning
[10]. To facilitate translational medical research in infectious diseases, an Infectious Dis-
ease Ontology (IDO) Consortium http://www.infectiousdiseaseontology.org/ has been
established. IDO is aimed to develop a suite of interoperable ontologies that jointly cover
the entire infectious disease domain, spanning infectious disease specialties and the clinical
care, public health, and biomedical research domains. The IDO suite of ontologies are
developed using a core-extension approach in which disease- or pathogen-specific ontolo-
gies are developed as extension ontologies from a common IDO core [11]. The IDO-core
ontology provides coverage of those entities relevant to infectious diseases generally,
including terms such as host, pathogen, focal infection, and herd immunity. Meanwhile,
the IDO extensions cover entities relevant to specific disease or pathogen types. The IDO-
core was developed within the framework of the Basic Formal Ontology (BFO) [9] and the
Ontology of General Medical Sciences (OGMS) [12]. The IDO-core terms have simple
and formal natural language definitions as well as formal logical expressions stated in
terms of relations from the OBO relation ontology and terms from IDO or other OBO
ontologies, such as the Gene Ontology (GO) [7]. Specific IDO extension ontologies (e.g.,
Brucellosis Ontology, Influenza Ontology [13], and Malaria Ontology [14]) are maintained
by experts from specific infectious disease areas. Different IDO extension ontologies are
developed from the core in a coordinated fashion that ensures interoperability among all
IDO extension ontologies.
In this paper, we report our development of a Brucellosis Ontology (IDOBRU) as an
IDO-core extension ontology that targets the brucellosis domain.
Results
In what follows, italics are used to refer to a specific term within IDOBRU where
appropriate. Prefix of an existing ontology is listed before one term, in such a form as
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file 1 provides detailed information of all ontology terms and relations used in this
manuscript.
IDOBRU general design and introduction
IDOBRU is an ontology that covers and crosses the biomedical domains of clinical
care, public health and biomedical research in the specific brucellosis field. IDOBRU
contains the vocabulary and terms from seven major aspects: host infection and zoono-
t i cd i s e a s et r a n s m i s s i o n, symptoms, virulence factors and pathogenesis, diagnosis,
intentional release, vaccine prevention, and treatment. The goal of IDOBRU is to
establish a knowledgebase of Brucella and brucellosis. The targeted users of IDOBRU
include brucellosis researchers, microbiologists, bioinformaticians, clinicians, govern-
ments and related decision makers.
The current IDOBRU version “Arbor Release” (version number 1.1.41 released on Octo-
ber 28, 2011) contains a total of 1503 terms, including 1469 classes, 26 object properties,
and 8 datatype properties. Among them, 414 terms are IDO-core-specific terms. In total,
IDOBRU includes 739 IDOBRU-specific terms, including 726 classes, 5 object properties
and 8 datatype properties. Following the principles of OBO Foundry, IDOBRU has reused
or adopted external ontologies that are OBO Foundry ontologies and candidate ontolo-
gies. IDOBRU fully imports the whole BFO, RO and IDO-core. Using the OntoFox [15]
software program, IDOBRU imports external terms from eight other existing ontologies
and resources: Chemical Entities of Biological Interest (CHEBI) [16], Gene Ontology [7],
Information Artifact Ontology (IAO) [17], NCBI Taxonomy database [18], Ontology for
Biomedical Investigations (OBI) [19], Ontology for General Medical Science (OGMS) [12],
Protein Ontology [20], and Vaccine Ontology (VO) [21] (Table 1). In total, IDOBRU has
imported 764 terms from 11 external ontologies. Figure 1 shows the major architecture of
IDOBRU that includes key top-level terms in IDOBRU. As shown in this figure, all brucel-
losis-specific terms are subclasses of terms from higher level ontologies including the
IDO-core, OGMS, OBI, VO, and GO.
According to an agreement between IDOBRU and the IDO-core development teams, a
“hub-and-spoke” model is adopted for the development of the IDO-core and IDO exten-
sion ontologies. Specifically, the IDO-core acts as the hub and plays a role as the mediator
for all extension ontologies, and infectious disease extension ontologies act as spokes. As a
principal in OBO foundry ontologies, an identifier is always bipartite, in the form of
ID-space:Local-ID, for example: IDO:0000001. Instead of using different ID-spaces and
Local-IDs for individual IDO extension ontologies, every extension ontology uses the
same ID-space: “IDO”, as the IDO-core. For example, an ID used for an IDOBRU term is
IDO:0100246, instead of IDOBRU:0000246. Unique ID blocks pre-assigned by the IDO-
core team are used to differentiate specific extension ontologies. This strategy has many
advantages: (1) to avoid duplicate terms and efforts; (2) to enforce the same best practice
for ontology development across different extension ontologies; and (3) to encourage bet-
ter collaboration and closer coordination between the IDO-core and IDO extension devel-
opment teams. Meanwhile, each extension ontology is developed independently and
maintains its own development repository site.
In the following sections, we will introduce IDOBRU representation of different
aspects of brucellosis in details.
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The genus Brucella is taxonomically placed in the alpha-2 subdivision of the class
NCBITaxon:Proteobacteria. Traditionally there are eight species of Brucella based on
the preferential host specificity: B. melitensis (goats), B. abortus (cattle), B. suis (swine),
Table 1 IDOBRU specific terms and terms imported to IDOBRU from 11 source
ontologies
# Ontology Classes Object
Properties
Datatype
Properties
Total
1 IDOBRU (Brucellosis Ontology) specific 726 5 8 739
Imported ontologies as whole
1 BFO (Basic Formal Ontology) 39 0 0 39
2 RO (Relation Ontology) 0 9 0 9
3 IDO (Infectious Disease Ontology) 411 3 0 414
4 OGMS (Ontology for General Medical
Science)
82 0 0 82
Imported from other external ontologies
1 OBI (Ontology for Biomedical Investigations) 12 7 0 19
2 NCBITaxon (NCBI Taxonomy) 103 0 0 103
3 IAO (Information Artifact Ontology) 7 2 0 9
4 VO (Vaccine Ontology) specific 68 0 0 68
5 CHEBI (Chemical Entities of Biological
Interest)
90 0 1 1
6 GO (Gene Ontology) 9 0 0 9
7 PRO (Protein Ontology) 1 0 0 1
Total 12 1469 26 8 1503
Figure 1 The major architecture of IDOBRU. Key top level ontology terms in IDOBRU are included.
Those terms that do not include any ontology acronyms are generated in the IDOBRU ontology. Each
arrow sign “¬” represents an is_a relation where a right side class term is a subclass of the term at the left
side of the arrow.
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and B. pinnipediae (seal) [22]. The first four species are pathogenic to humans in
decreasing order of severity, making brucellosis a zoonotic disease.
The zoonosis feature of brucellosis is captured by the term of IDO:zoonotic disposition.
In IDO, zoonotic disposition is defined as an infectious disposition that is the disposition
to be transmitted from an infected, non-human host to a human host [23]. Therefore, in
IDOBRU, Brucella is asserted as bearer of IDO:zoonotic disposition (Figure 2). For exam-
ple, B. abortus, a subclass of Brucella, can infect both cattle and human. As subclasses of
brucellosis pathogen role, both of the human brucellosis pathogen role and cattle brucello-
sis pathogen role are roles of B. abortus.D u r i n gt h eprocess of establishing B. abortus infec-
tion,t h ezoonotic disposition of Brucella is realized. An infected human or cattle is the
host of Brucella during the infection. Therefore, both Brucella infected human and
Brucella infected cattle are the bearer of Brucella host role. Brucella infected human (or
cattle) has disposition of human (or cattle) brucellosis , which is realized in the disease
course of human (or cattle) brucellosis (Figure 2).
To model the complicated infection and animal-to-human transmission mechanisms in
brucellosis, we used the following scenario as an example. A brucellosis human patient is
infected via drinking the unpasteurized Brucella-contaminated milk produced by a
Brucella-infected cow. The Brucella-infected cow produces milk that is contaminated with
Brucella during the Brucella-contaminated milk producing process,w h e r et h eBrucella-
contaminated milk producing disposition is realized. The Brucella-contaminated milk,a
specified output of this producing process, is drunk by the Brucella infected human when
he/she realizes a drinking function (Figure 2).
Figure 2 IDOBRU modeling of human and cattle brucellosis due to zoonotic Brucella infections and
transmission. The terms inside boxes represent ontology classes. The terms in the middle of arrows are
ontology relations.
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A symptom is a bodily feature that a patient observes. The brucellosis symptom is a
subclass of OGMS:symptom [12]. Brucellosis usually causes abortion and sterility in
non-human animals. Undulant fever, myalgia, and arthralgia of the large joints are the
main symptoms in human brucellosis patients [24]. As a use case, the human undulant
fever is modeled here (Figure 3). Undulant fever is a term with an ambiguous meaning.
It has been used as an alternative synonym for human brucellosis, as well as a symp-
tom of human brucellosis. In IDOBRU’s point of view, the reality of the undulant fever
is based on the fact that during the course of the disease, brucellosis patient’s tempera-
ture shows diurnal variation [25]. As a scenario of the temperature diurnal variation
process, a brucellosis human patient has a quality of elevated temperature measured
as 40°C in the afternoon, and then has a quality of normal temperature measured as
37.1°C in the morning. Both temperature elevation in the afternoon and temperature
staying normal in the morning are parts of the process of diurnal variation of tempera-
ture, which is a part of the human brucellosis disease course.T h ehuman brucellosis
symptom is a quality of brucellosis human patient. At the different time points, the
human patient has different temperature qualities as measured with different tempera-
ture numbers. It is noted that specific temperatures in different time points fall into
instance levels of our ontology rather than class levels of entity. However, the elevated
temperature and normal temperature without temporal part are considered as sub-
classes of BFO:Quality at the class level.
Modeling Brucella virulence factors and pathogenesis in IDOBRU
Brucella doesn’t bear the classic bacterial virulence factors as capsules, secreted pro-
teases, exotoxins, endotoxins, etc. As an intracellular bacterium, Brucella virulence
relies on its ability to survive and replicate in the vacuolar compartments of macro-
phages. The interaction between Brucella and macrophages is critical for the
Figure 3 IDOBRU modeling of Brucella undulant fever process. The two temperatures (37.1°C and
40.0°C) inside oval boxes are instances. All other terms inside boxes represent ontology classes. The terms
in the middle of arrows are ontology relations.
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order for Brucella to establish a successful infection: (a) the entry into host cell, (b) the
survival and (c) the replication within membrane-bound compartments in host cells,
particularly macrophages. The type IV secretion system encoded by Brucella virB
operon is required for the survival of Brucella inside replicative phagosomes in macro-
phages [28]. Brucella lipopolysaccharide (LPS) of smooth virulent Brucella strains is
required to prevent the phagosome-lysosome fusion in macrophages, allowing the sur-
vival and replication of Brucella inside macrophages [28,29]. Brucella VirB1 protein
and Brucella LPS, the two important virulence factors, are used as examples for viru-
lence factor modeling in IDOBRU (Figure 4).
In IDO-core, the terms related to virulence factor are IDO: virulence factor and IDO:
virulence factor disposition. IDO:virulence factor is the bearer of IDO: virulence factor
disposition. As an IDO extension, IDOBRU has Brucella virulence factor and Brucella
virulence factor disposition.U s i n gt h eBrucella-macrophage interaction as a scenario,
the Brucella virulence factor disposition is realized in the process of establishing
Brucella infection in macrophages. As a process entity, the process of establishing
Brucella infection in macrophages has three partial processes: establishment of Brucella
intracellular localization, Brucella survival in macrophages, and Brucella replication in
macrophages (Figure 4). The ‘part of’ relation (RO:part_of) has been asserted between
each of these partial processes and the process of establishing Brucella infection in
macrophage. Brucella VirB1,as u b t y p eo fBrucella protein, has the disposition as a
Brucella virulence factor disposition and participates in the processes of Brucella survi-
val in macrophages and Brucella replication in macrophages. Brucella LPS participates
in the processes of Brucella replication in macrophages, and Brucella entry into macro-
phages, which is a partial process of establishment of Brucella intracellular localization.
Figure 4 IDOBRU modeling of Brucella virulence factors and pathogenesis.T h et e r m si n s i d eb o x e s
represent ontology classes. The terms in the middle of arrows are ontology relations.
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protein and lipopolysaccharide. We asserted a term Brucella protein virulence factor as
as u b t y p eo fBrucella virulence factor in IDOBRU. The formal logic definitions of
Brucella virulence factor and Brucella protein virulence factor have been given as such:
Brucella virulence factor ≡ (part_of some Brucella) and (bearer_of some ‘Brucella
virulence factor disposition’)
Brucella protein virulence factor ≡ ’Brucella protein’ and (bearer_of some ‘Brucella
virulence factor disposition’)
After reasoning, Brucella VirB1 has been computed as a subclass of Brucella protein
virulence factor, and Brucella LPS as a subclass of Brucella virulence factor.
In total, 245 curated Brucella virulence factors have been imported into IDOBRU
from a MySQL database of the Brucella Bioinformatics Portal (BBP) [4].
Modeling Diagnosis of brucellosis in IDOBRU
Diagnosis of human brucellosis cannot be made solely on clinical grounds due to the
wide variety of its clinical manifestations. It is essential to confirm the diagnosis using
bacteriological and serological tests. Many assays (e.g., polymerase chain reaction or
PCR, ELISA, and agglutination assays) have been used for diagnosis of brucellosis [25].
The use of PCR allows for rapid and accurate diagnosis, and it is a rapid method to
confirm the infection of Brucella [30]. IDOBRU adopts the terminological framework
of OGMS for a top level representation of diseases, such as disease causes and mani-
festations, diagnosis, and other disease interpretations used in the clinic. According to
OGMS, diagnosis is defined as “a conclusion of an interpretive process that has as
input a clinical picture of a given patient and as output an assertion” [12]. Brucellosis
diagnosis is a subclass of OGMS:diagnosis. Based on different assays used in the diag-
nostic process, brucellosis diagnosis has many subclasses, e.g., brucellosis diagnosis by
PCR test, brucellosis diagnosis by ELISA, and brucellosis diagnosis by microscopy.
PCR assays have been frequently used for diagnosis. A PCR assay is different from
PCR amplification. The PCR amplification is a material transformation process with an
output of amplified PCR product. A PCR assay is designed for specific purposes (e.g.
detecting a target sequence for diagnosis) using PCR amplification. The PCR amplifica-
tion is a part of a PCR assay. To model brucellosis diagnosis, a PCR assay used to test a
Brucella gene omp-2 encoding for an outer membrane protein (OMP-2) from patient’s
blood sample is specifically studied [31] (Figure 5). First, the IDOBRU term PCR assay
for detecting Brucella omp-2 was asserted as a subclass of OGMS:laboratory test.U s i n g
brucellosis patient derived specimen as specified input, the PCR assay will generate an
output that is the laboratory finding of Brucella omp-2 detection. As a subclass of IAO:
information content entity, this specific laboratory finding is about the patient derived
specimen. The IAO relation is_about relates an information artifact to an entity. Sec-
ondly, this specific PCR assay has an integral part: PCR to amplify 193 bp region in Bru-
cella OMP-2 gene [31]. OBI:polymerase chain reaction has been imported from OBI, and
the PCR amplification of 193 bp region in Brucella OMP-2 gene is a subclass of OBI:poly-
merase chain reaction in IDOBRU. The inputs of the PCR amplification are: (a) Brucella
OMP-2 forward primer, (b) Brucella OMP-2 reverse primer, and (c) DNA extracted from
Brucella contaminated blood specimen. The output of this PCR amplification is the pro-
duct of PCR amplification of 169 bp region in Brucella OMP-2.F i n a l l y ,o n l yap o s i t i v e
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sion of Brucella infection. Using the laboratory finding of Brucella OMP-2 detection as
an input for the brucellosis diagnostic process, the output is human brucellosis diagnosis.
This diagnosis thus is_about the clinical manifestation of brucellosis (Figure 5).
The primer sequence information and PCR product described in above PCR experi-
ment are modeled as primer sequence data and PCR product sequence data, respec-
tively. All of the sequence data of primers and PCR product are parts of B. abortus
genome sequence data [31]. The relation denotes is defined in IAO that allows us to
assert the relationship between digital data of a DNA sequence and its corresponding
physical biological material sequence. In our case, PCR sequence data (a digital data
item) denotes PCR product of the Brucella OMP-2 PCR amplification. A ‘part-whole’
relation is used in two different types of entities here: a) The material entity: OMP-2
gene as part of B. abortus genome, which is part of the B. abortus bacterial cell that
exists in the blood specimen taken from the human patient. b) The information con-
tent entity: the OMP-2 gene sequence data as part of B. abortus genome sequence data.
Modeling brucellosis epidemiology and intentional release in IDOBRU
Many factors can affect the prevalence of brucellosis in various species of livestock.
Prevalence of brucellosis can vary according to climatic conditions, geography, species,
sex, age and diagnostic tests applied [32]. Although it has been eradicated in many
developed countries in Europe, Australia, Canada, Israel, Japan and New Zealand, bru-
cellosis remains an uncontrolled problem in regions of high endemicity such as the
Africa, Mediterranean, Middle East, parts of Asia and Latin America. Re-emergence of
b r u c e l l o s i si sr e p o r t e di nJ a p a n1 9 9 6 ,B u l g aria during 2005 to 2007 and FBH (Federa-
tion of Bosnia and Herzgovina) recently [25].
Figure 5 IDOBRU modeling of brucellosis diagnosis using PCR test. The terms inside boxes represent
ontology classes. The terms in the middle of arrows are ontology relations.
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brucellosis endemic site, brucellosis free site, brucellosis non-endemic site, brucellosis
surveillance , and more others, have been used to capture the knowledge of epidemiol-
ogy aspect of brucellosis. Since brucellosis is a zoonotic disease, the above classes have
subclasses both in human brucellosis and non-human brucellosis.
Brucella can be intentionally used as a bioterrorism weapon as an incapacitating
agent rather than a lethal agent. Although brucellosis causes low fatality rate, human
brucellosis is a notoriously debilitating disease, and brucellosis patients require pro-
longed treatment [24]. Brucella organisms can be aerosolized and released in infectious
doses, such as a sum of 10-500 virulent aerosol Brucella organisms. It is important to
disinfect Brucella once its release is identified. Most commercial disinfectants are effec-
tive at killing or neutralizing Brucella organisms. Bleach (10%) has been used as an
effective disinfectant to control the release of Brucella.
The intentional release of aerosolized Brucella is modeled (Figure 6). Both Brucella
and aerosolized Brucella has the role as a bioterrorism agent. The process of Brucella
intentional release is a OBI:planned process. The aerosolized Brucella has been produced
by the Brucella aerosolization process (a subtype of OBI:planned process), which is an
integral part of the Brucella intentional release process. When Brucella is used for the
intentional release, Brucella is a specified input in the process of Brucella intentional
release.W h e naBrucella bioterrorism attack occurs, the bleach disinfection of aeroso-
lized Brucella process can be initiated for the purpose of disinfection. The bleach that
bears a disinfectant role is a specified input in this process (Figure 6).
Modeling vaccine prevention of brucellosis in IDOBRU
Vaccination is the most effective means of reducing brucellosis in cattle, sheep and
goat [25]. Currently IDOBRU imports 66 Brucella vaccines from the Vaccine Ontology
(VO; http://www.violinet.org/vaccineontology[21], including four licensed animal
Brucella vaccines and 62 Brucella vaccine candidates that have been proven effective
in laboratory animal models [33]. Currently, there is no licensed human brucellosis
vaccine. Available animal vaccines may cause disease and are considered unsuitable for
use in humans. Nonetheless, a human Brucella vaccine is needed to protect the public
against human brucellosis and bioterrorism [34].
Figure 6 IDOBRU modeling of Brucella intentional release. The terms inside boxes represent ontology
classes. The terms in the middle of arrows are ontology relations.
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tective immunity induced by protective Brucella antigens. A protective antigen can sti-
mulate protective adaptive immune response against Brucella infection, and is used as
an active component of a vaccine. In IDOBRU, this Brucella-specific adaptive immune
response is a subclass of G O :a d a p t i v ei m m u n er e s p o n s e ,w h i c hi saGO:immune
response (Figure 7). For example, Brucella Cu/Zn superoxide dismutase (SodC), coded
by Brucella sodC gene, is a known Brucella protective antigen (bearer of the Brucella
protective antigen role) [35-37]. Brucella sodC gene has been used for as part of the B.
abortus DNA vaccine pcDNA-SOD [38] (Figure 7). Currently IDOBRU has imported
21 Brucella protective antigens from VO.
Modeling treatment of brucellosis in IDOBRU
Once brucellosis is diagnosed, a treatment will follow. The World Health Organization
(WHO) has recommended a standard method for treatment of uncomplicated brucel-
losis cases in adults and children eight years of age and older: doxycycline 100 mg
Figure 7 IDOBRU modeling of a Brucella protective antigen and induced immune response.T h e
terms inside boxes represent ontology classes. The terms in the middle of arrows are ontology relations.
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weeks [39]. This WHO treatment has been modeled in IDOBRU and described below
(Figure 8).
The planned process WHO standard treatment for human brucellosis in adults and
children eight years of age and older consists of two integral parts: 1) WHO standard
doxycycline treatment for human brucellosis;2 )WHO standard streptomycin treatment
for human brucellosis. Using doxycycline treatment as an example, administrating dox-
ycycline 100 mg twice a day is part of the example process. Its specified input is the
material entity 100 mg doxycycline with a quality of dose measured as 100 mg. A data-
type property, hasDailyfrequency, has been used for representing the frequency of the
administration of doxycycline and its value is 2. The required duration of the whole
treatment, is represented by the term continuous 6 weeks treatment duration, which is
a subclass of BFO:connected temporal region. Here we adopted the definition of con-
nected temporal region asserted in BFO version 1.1: “A temporal region [span:Tempor-
alRegion] every point of which is mediately or immediately connected with every other
point” [40]. Similar to the administration frequency, the 6 weeks’ duration is modeled
by another datatype property: ’hasDurationinDays value “42"^^integer’ [41]. Since the
treatment is limited to patients whose age is greater than 8 years’ old, in IDOBRU, the
age of a human patient is captured by the datatype property “hasAge“ with a “float
type” restriction. Then, the patient who is suitable for this treatment will be repre-
sented by the following constrain as: ‘human patient’ and (hasAge some float [> =
“8"^^float]).
Ontology reasoning using IDOBRU
Since IDOBRU is developed using the OWL format, OWL-based automated reasoning
can be done using reasoning programs within OWL editors or by developing new
SPARQL query and reasoning programs. As an example, we designed the following
Figure 8 IDOBRU modeling of brucellosis treatment using a WHO-recommended method.T h et w o
doses (100 mg and 1 g) inside oval boxes are instances. The terms inside square boxes represent ontology
classes. The phrase in the dotted box is an axiom. Those phrases inside the other boxes are datatype
properties. The terms in the middle of arrows are ontology relations.
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antigens?” In IDOBRU, a Brucella virulence factor is logically defined as “something
that is a bearer of some Brucella virulence factor disposition“. A protective antigen is
logically defined as “something that is a bearer of some Brucella protective antigen
role“. To answer this question, the following query was performed in the DL Query tab
of the OWL editor Protégé 4:
(bearer_of some ‘Brucella protective antigen role’) and (bearer_of some ‘Brucella viru-
lence factor disposition’)
The answers to this query are: Brucella lipopolysaccharide and Brucella sodC and
their six subclasses: Brucella abortus lipopolysaccharide, Brucella abortus SodC, Bru-
cella melitensis lipopolysaccharide, Brucella melitensis SodC, Brucella ovis lipopolysac-
charide and Brucella suis lipopolysaccharide (Figure 9).
We have also developed an IDOBRU SPARQL query interface at http://www.phidias.
us/bbp/idobru/sparql/index.php. A SPARQL query script has been generated to obtain
the same answers by querying the same question (see Additional file 2).
Discussion
Our approach of developing IDOBRU combines a top-down and bottom-up realism
methodology [42]. In terms of the top-down method, we started by making IDO-core
Figure 9 DL Query window in Protégé 4.A nO W LD Lq u e r yo fBrucella virulent factors also being
protective antigens using the OWL editor Protégé 4. The query script is shown on the top. The results are
displayed at the bottom.
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IDO-core terms as super-classes. The bottom-up method is to identify the most speci-
fic terms by using scenarios, and then generalize them into higher ontology classes.
The prior knowledge of upper ontologies and existing ontologies, especially BFO, RO,
IDO, OGMS, VO, and OBI, is essential for the development of IDOBRU. Before a new
term is generated, we shall check whether or not this new term and its possible upper
level term have existed in other ontologies. Extensive discussion is often needed to
achieve a consensus in new term definition.
The limitations of upper ontologies limit ontology development in IDOBRU. For
example, the ontological theory of signs and symptoms and their relations to patholo-
gical processes has not been well-developed yet. OGMS is in the very early stages of
addressing this need [12]. Since it is one of the most important features of the clinical
manifestation of human brucellosis, IDOBRU tried to model the undulant fever pro-
cess (Figure 3). After several rounds of debating and discussing in the community of
IDO, finally the agreement has been achieved: (a) the term elevated temperature is a
BFO:Quality, and it is the quality of the human brucellosis patient;a n d( b )t h ebrucel-
losis diurnal variation fever process is a subclass of OGMS: pathological bodily process.
IDOBRU will evolve while other ontologies make their progress.
IDOBRU also has its own limitations. First, IDOBRU is still at the early stage of its
development. As a knowledgebase, the information about brucellosis in IDOBRU is
still limited. For example, while we have modeled one PCR assay for brucellosis diag-
nosis in IDOBRU, many other brucellosis diagnostic assays have been reported in the
literature and collected in online resources including the BBP [4]. We also need to
model other diagnosis assays including many serological diagnosis methods. Another
limitation of IDOBRU exists in its coverage of epidemiological terms. During the
course of our IDOBRU development, a large number of epidemiological terms have
been generated. Among them, many terms (e.g., infectious disease endemic site) are
not available in current IDO-core. Other IDO extension ontologies (e.g., Influenza
Ontology) have also been developing their epidemiological terms. Therefore, closer col-
laborations among the IDO-core and IDO extension ontologies are needed.
Currently, several IDO extensions are being developed, such as Malaria Ontology
[14], Influenza Ontology [13], Staphylococcus aureus Ontology, and Tuberculosis
Ontology http://infectiousdiseaseontology.org/page/Extensions. Malaria Ontology was
reported and published before an IDO-core was released [14]. Staphylococcus aureus
Ontology was one of the first bacterial extension ontologies developed and has been
well integrated with the IDO-core. Both S. aureus and M. tuberculosis are Gram-posi-
tive bacteria. So far Brucella has been the only Gram-negative bacterium being studied
for the purpose of an IDO extension ontology development. IDOBRU is the first IDO
extension ontology that is published after the official release of the IDO-core. It pro-
vides a useful real world example of using the IDO-core terms for development of an
IDO extension. To our knowledge, IDOBRU is the first ontology that logically models
several key topics of an infectious disease, including host infection, zoonotic disease
transmission, symptoms, virulence factors and pathogenesis, diagnosis, intentional
release relevant to bioterrorism, and treatment.
IDOBRU can be used for several applications. First of all, serving as a knowledgebase
of Brucella and brucellosis, IDOBRU captures the knowledge extracted from
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Page 14 of 18biomedical bench research, clinical practices, and public health. Secondly, owing to the
parseable and machine understandable nature of the ontology, IDOBRU supports Bru-
cella and brucellosis data exchange, data integration, and automated reasoning. IDO-
BRU uses BFO, RO and other existing ontologies such as OBI and OGMS. Therefore,
the IDOBRU information can easily be integrated with other ontologies and processed
with software programs developed based on OBO Foundry Principles. Finally, the
development of IDOBRU may serve as an example to model infectious diseases caused
by other microbial pathogens. Once many other infectious diseases are modeled using
the same framework, it is possible not only to compare different infectious diseases
automatically, but also to discover new knowledge in infectious disease domain.
Conclusions
IDOBRU is a brucellosis-centric ontology and a knowledge-centric platform. IDOBRU
can be used as a brucellosis knowledgebase and is applicable for brucellosis data
exchange, data integration, and automated reasoning.
Methods
IDOBRU editing
IDOBRU was developed using the format of W3C standard Web Ontology Language
(OWL2) http://www.w3.org/TR/owl-guide/. For efficient editing of IDOBRU, the Pro-
tégé 4.1 OWL ontology editor http://protege.stanford.edu/ was used.
Existing ontology term import
The whole ontologies of BFO, RO and IDO-core have been imported into IDOBRU
using the OWL ontology importing feature. A web server OntoFox http://ontofox.
hegroup.org/[15] was used to import external terms from existing ontologies to
IDOBRU.
IDOBRU access and licensing
The latest version of IDOBRU is always available at http://svn.code.sf.net/p/idobru/
code/trunk/trunk/src/ontology/brucellosis.owl. In addition, IDOBRU has been depos-
ited in the repositories of NCBO BioPortal http://purl.bioontology.org/ontology/IDO-
BRU. The IDOBRU source code is freely available under the Apache License 2.0. This
licensing allows IDOBRU users to freely distribute and use IDOBRU.
IDOBRU visualization and term search
To make it convenient for users to browse and search the definitions and usages of
IDOBRU terms and their relations, we have developed a user-friendly IDOBRU Brow-
ser using the Ontobee linked ontology browser system http://www.ontobee.org/brow-
ser/index.php?o=IDOBRU.
SPARQL query of IDOBRU
The IDOBRU SPARQL query web page is built as a software program compatible with
the IDOBRU website http://www.phidias.us/bbp/idobru located in the Brucella Bioin-
formatics Portal (BBP; http://www.phidias.us/bbp) [4,43]. To develop this program, the
IDOBRU was stored in a Virtuoso RDF store located in one HP ProLiant DL380 G6
server that runs the Red Hat Linux operating system (Red Hat Enterprise Linux 5
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Page 15 of 18server). PHP scripting language was used for developing the SPARQL web interface.
The SPARQL queries provided by a user are implemented through HTTP against the
RDF stores.
Additional material
Additional file 1: Ontology classes used in the manuscript. The file includes the detailed information about all
ontology classes and relations used in the manuscript.
Additional file 2: SPARQL script. This SPARQL script is used to query the IDOBRU: “What Brucella virulence
factors are also protective antigens?”.
List of abbreviations
BFO: Basic Formal Ontology; BBP: Brucella Bioinformatics Portal; CHEBI: Chemical Entities of Biological Interest; DL;
Description Logic; ELISA: Enzyme-Linked Immunosorbent Assay; GO: Gene Ontology; IAO: Information Artifact
Ontology; IDO: Infectious Disease Ontology; IDO-core: Infectious Disease Ontology core; LPS: lipopolysaccharide; NCBI:
The National Center for Biotechnology Information; NCBO: The National Center for Biomedical Ontology; OBI:
Ontology for Biomedical Investigations; OBO: The Open Biomedical Ontologies; OGMS: Ontology for General Medical
Science; OWL: Web Ontology Language; PATRIC: Pathosystems Resource Integration Center; PCR: Polymerase Chain
Reaction; PHP: Hypertext Preprocessor; PO: Protein Ontology; RDF: Resource Description Framework; RO: OBO Relation
Ontology; ro_proposed: RO proposed version; SPARQL: SPARQL Protocol and RDF Query Language; URI: Uniform
Resource Identifier; VIOLIN: Vaccine Investigation and Online Information Network; VO: Vaccine Ontology; WHO: World
Health Organization; XML: Extensible Markup Language.
Acknowledgements
This work has been supported by grant R01AI081062 from the National Institute of Allergy and Infectious Diseases.
We acknowledge Dr. Salwa Ali’s contribution in the development of IDOBRU by editing many epidemiology-
associated terms. We appreciate the discussions and advices provided by Alan Ruttenberg, Barry Smith, Lindsay
Cowell, Richard Scheuermann, and other IDO consortium members during and after three related IDO workshops. We
also appreciate active discussions and support by all OBI developers. We gratefully acknowledge the critical review
and editing of this manuscript by Dr. George W. Jourdian from the University of Michigan Medical School and Dr.
Lindsay Cowell from the University of Texas Southwestern Medical Center at Dallas.
Author details
1Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
2Department
of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
3Center for
Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Authors’ contributions
YL, Primary IDOBRU developer, use case testing, drafting of manuscript. ZX, IDOBRU developer, Webmaster, software
programmer, database administrator, and manuscript editing. YH, IDOBRU developer, project design and
management, brucellosis domain expert, use case testing, and drafting of manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 May 2011 Accepted: 31 October 2011 Published: 31 October 2011
References
1. Madkour MM: Brucellosis. Kent: Butterworths; 1989.
2. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV: The new global map of human brucellosis. Lancet Infect
Dis 2006, 6(2):91-99.
3. Davis RG: The AbCs of bioterrorism for veterinarians, focusing on Category B and C agents. J Am Vet Med Assoc
2004, 224(7):1096-1104.
4. Xiang Z, Zheng W, He Y: BBP: Brucella genome annotation with literature mining and curation. BMC Bioinformatics
2006, 7:347.
5. Snyder EE, Kampanya N, Lu J, Nordberg EK, Karur HR, Shukla M, Soneja J, Tian Y, Xue T, Yoo H, Zhang F, Dharmanolla C,
Dongre NV, Gillespie JJ, Hamelius J, Hance M, Huntington KI, Jukneliene D, Koziski J, Mackasmiel L, Mane SP, Nguyen V,
Purkayastha A, Shallom J, Yu G, Guo Y, Gabbard J, Hix D, Azad AF, Baker SC, et al: PATRIC: the VBI PathoSystems
Resource Integration Center. Nucleic Acids Res 2007, , 35 Database: D401-406.
6. Xiang Z, Todd T, Ku KP, Kovacic BL, Larson CB, Chen F, Hodges AP, Tian Y, Olenzek EA, Zhao B, Colby LA, Rush HG,
Gilsdorf JR, Jourdian GW, He Y: VIOLIN: vaccine investigation and online information network. Nucleic Acids Res 2008,
, 36 Database: D923-928.
7. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA,
Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene
ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25(1):25-29.
Lin et al. Journal of Biomedical Semantics 2011, 2:9
http://www.jbiomedsem.com/content/2/1/9
Page 16 of 188. Smith B, Ceusters W, Klagges B, Kohler J, Kumar A, Lomax J, Mungall C, Neuhaus F, Rector AL, Rosse C: Relations in
biomedical ontologies. Genome Biol 2005, 6(5):R46.
9. Smith B, Ashburner M, Rosse C, Bard J, Bug W, Ceusters W, Goldberg LJ, Eilbeck K, Ireland A, Mungall CJ, OBI
Consortium, Leontis N, Rocca-Serra P, Ruttenberg A, Sansone SA, Scheuermann RH, Shah N, Whetzel PL, Lewis S: The
OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol 2007,
25(11):1251-1255.
10. Bodenreider O: Biomedical ontologies in action: role in knowledge management, data integration and decision
support. Yearb Med Inform 2008, 67-79.
11. Cowell LG, Smith B: Infectious Disease Ontology. In Infectious Disease Informatics. Edited by: Sintchenko V. New York
Dordrecht Heidelberg London: Springer; 2010:373-395.
12. Scheuermann R, Ceusters W, Smith B: Toward an Ontological Treatment of Disease and Diagnosis. The 2009 AMIA
Summit on Translational Bioinformatics: 2009; San Francisco 116-120.
13. Influenza Ontology. [http://influenzaontologywiki.igs.umaryland.edu/wiki/index.php/Main_Page].
14. Topalis P, Mitraka E, Bujila I, Deligianni E, Dialynas E, Siden-Kiamos I, Troye-Blomberg M, Louis C: IDOMAL: an ontology
for malaria. Malar J 2010, 9:230.
15. Xiang Z, Courtot M, Brinkman RR, Ruttenberg A, He Y: OntoFox: web-based support for ontology reuse. BMC Res
Notes 2010, 3:175.
16. Degtyarenko K, de Matos P, Ennis M, Hastings J, Zbinden M, McNaught A, Alcantara R, Darsow M, Guedj M,
Ashburner M: ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res 2008, , 36
Database: D344-350.
17. IAO ontology. [http://code.google.com/p/information-artifact-ontology/].
18. Sayers EW, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, DiCuccio M, Edgar R, Federhen S,
Feolo M, Geer LY, Helmberg W, Kapustin Y, Landsman D, Lipman DJ, Madden TL, Maglott DR, Miller V, Mizrachi I,
Ostell J, Pruitt KD, Schuler GD, Sequeira E, Sherry ST, Shumway M, Sirotkin K, Souvorov A, Starchenko G, Tatusova TA,
et al: Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2009, , 37
Database: D5-15.
19. Brinkman RR, Courtot M, Derom D, Fostel JM, He Y, Lord P, Malone J, Parkinson H, Peters B, Rocca-Serra P,
Ruttenberg A, Sansone SA, Soldatova LN, Stoeckert CJ Jr, Turner JA, Zheng J, OBI consortium: Modeling biomedical
experimental processes with OBI. J Biomed Semantics 2010, 1(Suppl 1):S7.
20. Natale DA, Arighi CN, Barker WC, Blake J, Chang TC, Hu Z, Liu H, Smith B, Wu CH: Framework for a protein ontology.
BMC Bioinformatics 2007, 8(Suppl 9):S1.
21. He Y, Cowell LG, Diehl AD, Mobley H, Peters B, Ruttenberg A, Scheuermann R, Brinkman RR, Courtot M, Mungall C,
Xiang Z, Chen F, Todd T, Colby LA, Rush H, Whetzel T, Musen MA, Athey BD, Omenn GS, Smith B: VO: Vaccine
Ontology. The 1st International Conference on Biomedical Ontology (ICBO 2009): 2009; Buffalo, NY, USA Nature Precedings;
2009.
22. Cloeckaert A, Verger JM, Grayon M, Paquet JY, Garin-Bastuji B, Foster G, Godfroid J: Classification of Brucella spp.
isolated from marine mammals by DNA polymorphism at the omp2 locus. Microbes Infect 2001, 3(9):729-738.
23. IDO ontology. [http://purl.obolibrary.org/obo/ido.owl].
24. Franco MP, Mulder M, Gilman RH, Smits HL: Human brucellosis. Lancet Infect Dis 2007, 7(12):775-786.
25. Madkour MM: Madkour’s brucellosis. Berlin; London: Springer; 2001.
26. Chen F, Ding X, Ding Y, Xiang Z, Li X, Ghosh D, Schurig GG, Sriranganathan N, Boyle SM, He Y: Proinflammatory
Caspase-2-Mediated Macrophage Cell Death Induced by a Rough Attenuated Brucella suis Strain. Infect Immun
2011, 79(6):2460-2469.
27. Chen F, He Y: Caspase-2 mediated apoptotic and necrotic murine macrophage cell death induced by rough
Brucella abortus. PLoS One 2009, 4(8):e6830.
28. Roop RM, Bellaire BH, Valderas MW, Cardelli JA: Adaptation of the Brucellae to their intracellular niche. Mol Microbiol
2004, 52(3):621-630.
29. He Y, Reichow S, Ramamoorthy S, Ding X, Lathigra R, Craig JC, Sobral BW, Schurig GG, Sriranganathan N, Boyle SM:
Brucella melitensis triggers time-dependent modulation of apoptosis and down-regulation of mitochondrion-
associated gene expression in mouse macrophages. Infect Immun 2006, 74(9):5035-5046.
30. Romero C, Pardo M, Grillo MJ, Diaz R, Blasco JM, Lopez-Goni I: Evaluation of PCR and indirect enzyme-linked
immunosorbent assay on milk samples for diagnosis of brucellosis in dairy cattle. J Clin Microbiol 1995,
33(12):3198-3200.
31. Leal-Klevezas DS, Martinez-Vazquez IO, Lopez-Merino A, Martinez-Soriano JP: Single-step PCR for detection of Brucella
spp. from blood and milk of infected animals. J Clin Microbiol 1995, 33(12):3087-3090.
32. Gul S, Khan A: Epidemiology and epizootology of brucellosis: A review. Pakistan Veterinary Journal 2007, 27(3):7..
33. He Y, Xiang Z: Bioinformatics analysis of Brucella vaccines and vaccine targets using VIOLIN. Immunome Res 2010,
6(Suppl 1):S5.
34. Perkins SD, Smither SJ, Atkins HS: Towards a Brucella vaccine for humans. FEMS Microbiol Rev 2010.
35. Yang B, Sayers S, Xiang Z, He Y: Protegen: a web-based protective antigen database and analysis system. Nucleic
Acids Res 2011, , 39 Database: D1073-1078.
36. He Y, Vemulapalli R, Schurig GG: Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu, Zn superoxide
dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infect
Immun 2002, 70(5):2535-2543.
37. Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle SM, Schurig GG: Overexpression of protective antigen as a
novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect Immun 2000, 68(6):3286-3289.
38. Munoz-Montesino C, Andrews E, Rivers R, Gonzalez-Smith A, Moraga-Cid G, Folch H, Cespedes S, Onate AA: Intraspleen
delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+
and CD8+ T cells. Infect Immun 2004, 72(4):2081-2087.
39. Corbel MJ: Brucellosis in humans and animals. World Health Organization 2006 2005, 102.
40. Grenon P: Spatio-temporality in Basic Formal Ontology. In IFOMIS reports. Edited by: Grenon P. Leipzig: Institute for
Formal Ontology and Medical Information Science at the Faculty of Medicine of the University of Leipzig; 2003:89.
Lin et al. Journal of Biomedical Semantics 2011, 2:9
http://www.jbiomedsem.com/content/2/1/9
Page 17 of 1841. The Manchester OWL Syntax. [http://www.co-ode.org/resources/reference/manchester_syntax/].
42. Smith B, Ceuster W: Ontological realism: A methodology for coordinated evolution of scientific ontologies. Applied
Ontology 2010, 5(3-4):139-188.
43. Xiang Z, Tian Y, He Y: PHIDIAS: a pathogen-host interaction data integration and analysis system. Genome Biol 2007,
8(7):R150.
doi:10.1186/2041-1480-2-9
Cite this article as: Lin et al.: Brucellosis Ontology (IDOBRU) as an extension of the Infectious Disease Ontology.
Journal of Biomedical Semantics 2011 2:9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lin et al. Journal of Biomedical Semantics 2011, 2:9
http://www.jbiomedsem.com/content/2/1/9
Page 18 of 18